Edmond DE Rothschild Holding S.A. Purchases 29,026 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Edmond DE Rothschild Holding S.A. increased its position in Exact Sciences Co. (NASDAQ:EXAS) by 12.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 267,648 shares of the medical research company’s stock after purchasing an additional 29,026 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Exact Sciences were worth $15,039,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allstate Corp purchased a new position in shares of Exact Sciences in the fourth quarter worth $311,000. DnB Asset Management AS increased its holdings in Exact Sciences by 23.4% in the 4th quarter. DnB Asset Management AS now owns 226,857 shares of the medical research company’s stock worth $12,747,000 after buying an additional 43,006 shares in the last quarter. Pictet Asset Management Holding SA raised its position in Exact Sciences by 2.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 69,341 shares of the medical research company’s stock worth $3,896,000 after buying an additional 1,609 shares during the last quarter. Norges Bank bought a new position in Exact Sciences during the 4th quarter valued at about $50,625,000. Finally, Sava Infond d.o.o. purchased a new stake in shares of Exact Sciences during the 4th quarter valued at about $346,000. 88.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EXAS. Bank of America lowered their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Benchmark reissued a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Royal Bank of Canada initiated coverage on Exact Sciences in a report on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 price objective for the company. Scotiabank increased their target price on Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. Finally, Guggenheim set a $60.00 target price on Exact Sciences and gave the stock a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $70.26.

Exact Sciences Stock Down 3.0 %

EXAS opened at $43.66 on Monday. The stock has a market cap of $8.11 billion, a price-to-earnings ratio of -7.84 and a beta of 1.25. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The firm’s fifty day moving average is $49.71 and its 200 day moving average is $57.75. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. On average, sell-side analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.